Prophylactic Medications Taken by Healthcare Workers for COVID‑19; A Mixed Methods Study from South India
Abstract
Keywords
Full Text:
PDFReferences
WHO calls for healthy, safe and decent working conditions for
all health workers, amidst COVID‑19 pandemic. Available from:
https://www.who.int/news‑room/detail/28-04-2020-who-calls-forhealthy-safe-and-decent-working-conditions-for-all-health-workersamidst-covid-19-pandemic. [Last accessed on 2020 Jun 28].
Sookaromdee P, Wiwanitkit V. Precautions list of risk countries
with COVID‑19 for primary prevention: Experience on case
traveling from the country out of the list. Int J Prev Med
;11:66.
Adams JG, Walls RM. Supporting the health care workforce
during the COVID‑19 global epidemic. JAMA 2020;323:1439‑40.
FDA cautions against use of hydroxychloroquine or chloroquine
for COVID‑19 outside of the hospital setting or a clinical trial
due to risk of heart rhythm problems. FDA. Available from:
https://www.fda.gov/drugs/drug-safety-and-availability/fdacautions-against-use-hydroxychloroquine-or-chloroquine-covid19-outside-hospital-setting-or. [Last accessed on 2020 Jun 28].
CDC removes unusual guidance to doctors about drug favored
by Trump ‑ Reuters. Available from: https://in.reuters.com/
article/us‑health‑coronavirus‑usa‑cdcguidance/cdc-removesunusual-guidance-to-doctors-about-drug-favored-by-trumpidINKBN21P39R. [Last accessed on 2020 Jun 28].
Recommendation for empiric use of hydroxy‑chloroquine
for prophylaxis of SARS-CoV‑2 infection.
Available from: https://www.mohfw.gov.in/pdf/
A d v i s o r y o n t h e u s e o f H y d r o x y c h l o r o q u i n a s p r o p h y l a x
isforSARSCoV2infection.pdf. [Last accessed on 2020 Jun 28].
Revised advisory on the use of Hydroxychloroquine (HCQ) as
prophylaxis for SARS‑CoV‑2 infection. Available from: https://
www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_
the_use_of_HCQ_SARS_CoV2_infection.pdf. [Last accessed on
Jun 28].
Principi N, Esposito S. Chloroquine or hydroxychloroquine for
prophylaxis of COVID‑19. Lancet Infect Dis 2020;20:1118.
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine
and hydroxychloroquine in the treatment of COVID‑19 with or
without diabetes: A systematic search and a narrative review
with a special reference to India and other developing countries.
Diabetes Metab Syndr Clin Res Rev 2020;14:241‑6.
Assessment of Evidence for COVID‑19 Related Treatments.
Available from: https://www.ashp.org/‑/media/assets/
pharmacy‑practice/resource‑centers/Coronavirus/docs/
ASHP‑COVID‑19‑Evidence‑Table.ashx? [Last accessed on 2020
Jun 28].
Gautret P, Lagier J‑C, Parola P, Hoang VT, Meddeb L, Mailhe M,
et al. Hydroxychloroquine and azithromycin as a treatment of
COVID‑19: Results of an open‑label non‑randomized clinical
trial. Int J Antimicrob Agents 2020;56:105949.
HYDROXYCHLOROQUINE SULFATE TABLETS, USP.
Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2017/009768s037s045s047lbl.pdf. [Last accessed on 2020
Jun 28].
Aleebrahim‑Dehkordi E, Reyhanian A, Hasanpour‑Dehkordi A.
Clinical manifestation and the risk of exposure to
SARS‑CoV‑2 (COVID‑19). Int J Prev Med 2020;11:86.
Kapoor A, Pandurangi U, Arora V, Gupta A, Jaswal A,
Nabar A, et al. Cardiovascular risks of hydroxychloroquine in
treatment and prophylaxis of COVID‑19 patients: A scientific
statement from the Indian Heart Rhythm Society. Indian Pacing
Electrophysiol J 2020;20:117‑20.
Improving health worker performance: In search of promising
practices. Available from: https://www.who.int/hrh/resources/
improving_hw_performance.pdf?ua=1. [Last accessed on 2020
Jun 28].